enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
Key figures
- Insider buysLast 90 days, $10.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 11
- 13F valueReported value at the end of Q2 2026
- $1.54M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ENGNW, Q2 2026
No superinvestor reported holding ENGNW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by enGene Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:40 PM ET | Sep 22 | 2 days | Grossman WilliamInterim Chief Medical Officer | PPurchase | +5.10K | $1.97 | +$10.1K | New position5.10K after | |
| Nov 1, 2024 (view filing)4:15 PM ET | Oct 30 | 2 days | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +561.8K | $8.90 | +$5.00M | +22.7%3.03M after | |
| Oct 18, 2024 (view filing)4:15 PM ET | Dec 27, 2023-Oct 8, 2024 | 296 daysLate | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +470.6K | $6.40 | +$3.01M | +23.5%2.47M after | 13 lots |
| Oct 1, 2024 (view filing) | Sep 27 | 4 days | Cooper Ronald Harold WilfredChief Executive Officer | PPurchase | +10.0K | $5.70 | +$57.0K | New position10.0K after | |
| Apr 22, 2024 (view filing) | Apr 18-22 | 4 days | Fonds De Solidarite Des Travailleurs Du Quebec10% Owner | SSale | −52.5K | $15.00 | −$788.0K | −1.7%3.04M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in enGene Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 2,878,148 | $834.4K | 0.11% | 00.0% | Unchanged |
| BVF Inc | 945,402 | $274.1K | 0.01% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 511,177 | $148.2K | 0.02% | 00.0% | Unchanged |
| Caption Management, LLC | 333,675 | $96.7K | 0.00% | +333,675 | New |
| LMR Partners LLP | 309,763 | $89.8K | 0.00% | −10,924−3.4% | Reduced |
| Aristeia Capital LLC | 197,678 | $47.7K | 0.00% | +33,167+20.2% | Added |
| D. E. Shaw & Co., Inc. | 104,622 | $30.3K | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 31,545 | $9.15K | 0.00% | +31,545 | New |
| StoneX Group Inc. | 10,371 | $8.92K | 0.00% | +10,371 | New |
| CSS LLC | 16,895 | $4.90K | 0.00% | 00.0% | Unchanged |